RMTG · Regenerative Medical Technology Group Inc.
$0.10
-0.01 (-5.34%)
At close · Sep 1
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $79,484,265 and a working capital deficit of $40,328,417 as of June 30, 2026, and future losses are anticipated. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.18M
Shares
13.74M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.1M
+24.2%
FY2025
Net Income
-$7.81M
-40.4%
FY2025
Gross Margin
55.11%
-13.6pp
FY2025
Operating Margin
-17%
-19pp
FY2025
Diluted EPS
-$0.62
-40.9%
FY2025
Operating Cash Flow
-$706.52K
-183.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $9.41M | $5.1M | $4.11M | $2.41M | $1.53M | $437.89K | $55.08K | $30.1K | $50.12K | $29.24K | |
| $3.79M | $2.29M | $1.28M | $734.29K | $653.26K | $287.75K | $43.95K | $55.52K | $68.33K | $4810 | |
| $5.63M | $2.81M | $2.82M | $1.68M | $876.97K | $150.14K | $11.13K | -$25.42K | -$18.22K | $24.43K | |
| — | 55.11% | 68.73% | 69.53% | 57.31% | 34.29% | 20.2% | -84.45% | -36.35% | 83.55% | |
| $1.76M | $1.12M | $798.32K | $752.53K | $424.26K | $149.37K | $29.87K | $31.36K | $43.06K | $91.98K | |
| — | — | — | — | $8.2M | — | — | — | — | — | |
| $97.54K | $97.54K | $97.54K | $97.54K | — | — | — | — | — | — | |
| $362.93K | $281.07K | $220.56K | $310.1K | $152.74K | $40.86K | $800 | $800 | $200 | — | |
| $5.58M | $3.68M | $2.74M | $2.39M | $2.06M | $10.07M | $459.55K | $1.57M | $236.98K | $525.07K | |
| $43.73K | -$867.16K | $81.18K | -$715.23K | — | — | — | — | — | — | |
| — | -17% | 1.98% | -29.68% | — | — | — | — | — | — | |
| $406.65K | -$586.1K | $301.74K | -$405.12K | — | — | — | — | — | — | |
| $9.92M | $7.45M | $5.64M | $6.49M | — | $2.72M | $4.2M | $570.99K | $528.4K | $383.66K | |
| -$9.43M | -$6.95M | -$5.64M | -$9.1M | -$4.4M | -$2.72M | — | — | — | $2226 | |
| — | -$1.64M | -$1.16M | -$2.06M | -$1.16M | -$2.71M | — | — | — | — | |
| -$9.39M | -$7.81M | -$5.56M | -$9.81M | -$5.51M | -$12.88M | -$5.9M | -$2.51M | -$2.06M | -$377.01K | |
| — | -153.18% | -135.43% | -407.21% | -359.87% | -2942.42% | -10703.47% | -8335.2% | -4105.61% | -1289.31% | |
| USD/shares | -$0.73 | -$0.62 | -$0.44 | -$0.79 | -$0.45 | -$1.12 | -$0.63 | -$0.47 | -$0.50 | — |
| USD/shares | -$0.73 | -$0.62 | -$0.44 | -$0.79 | -$0.45 | -$1.12 | — | — | — | — |
| shares | — | 12.63M | 12.53M | 12.45M | 12.22M | 11.48M | 9.34M | 5.31M | 4.09M | 3.47M |
| shares | — | 12.63M | 12.53M | 12.45M | 12.22M | 11.48M | — | — | 4.09M | 3.47M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.02×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 85 similar-size Biotechnology companies (of 514 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product Supplies | $2,024,573 | $1,748,961 | $1,329,159 | $866,104 | $209,706 |
| Patient Procedures | $1,874,386 | $1,371,654 | $318,999 | $221,255 | — |
| Training | $1,125,521 | $809,654 | $599,425 | $279,404 | $112,970 |
| Equipments | $75,835 | $177,225 | $162,370 | $163,460 | $115,211 |